Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gaikwad (Launceston (TAS), Australia), W. Lu (Launceston (TAS), Australia), S. Dey (Launceston (TAS), Australia), P. Bhattarai (Launceston (TAS), Australia), C. Chia (Launceston (TAS), Australia), J. Larby (Launceston (TAS), Australia), G. Haug (Launceston (TAS), Australia), S. Myers (Launceston (TAS), Australia), S. Brake (Launceston (TAS), Australia), J. Jaffar (Melbourne, Australia), G. Westall (Melbourne, Australia), G. Singhera (Vancouver, Canada), T. Hackett (Vancouver, Canada), J. Markos (Launceston (TAS), Australia), M. Eapen (Launceston (TAS), Australia), S. Sohal (Launceston (TAS), Australia). Arterial remodelling in patients with idiopathic pulmonary fibrosis (IPF) and the possible role of endothelial to mesenchymal transition (EndMT). 1222

Member's Comments

No comment yet.

Related content which might interest you: Arterial stiffness and endothelial dysfunction in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 IL-11 promotes pulmonary vascular remodeling and lung fibrosis through the activation of endothelial to mesenchymal transition. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Epidermal growth factor receptor (EGFR) activation is required for TGFbeta1-induced epithelial-mesenchymal transition (EMT) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Endothelial progenitor cells and pulmonary vascular remodeling in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 435s Year: 2004 Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? Source: Eur Respir J, 56 (4) 2003167; 10.1183/13993003.03167-2020 Year: 2020 RhoA signalling influences cyclin D1 expression and associated fibroblast turnover: implications for idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung Year: 2009 Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 PDGFRa and aSMA mark two distinct mesenchymal cell populations involved in parenchymal and vascular remodeling in pulmonary fibrosis. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 The mechanism of epithelial-mesenchymal transition (EMT) in pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 823s Year: 2006 MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009 Pulmonary vascular involvement in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 28S-32S Year: 2003 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Oral presentation: Endothelial to mesenchymal transition (EnMT) as a mechanism of alveolar septal fibrosis/ remodelling in emphysema Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Circulating endothelial progenitor cells in patients with idiopathic pulmonary fibrosis (preliminary results) Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015